Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 7/20 | 0.52 |
| ▸ | ATR | Q13535 | 7/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | MTOR | P42345 | 13/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 9/20 | 0.51 |
| ▸ | PIK3CD | O00329 | 7/20 | 0.51 |
| ▸ | PIK3CB | P42338 | 6/20 | 0.51 |
| ▸ | PIK3CG | P48736 | 6/20 | 0.51 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.49 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.49 |
| ▸ | FECH | P22830 | 1/20 | 0.49 |
| ▸ | CLK1 | P49759 | 1/20 | 0.49 |
| ▸ | GSK3A | P49840 | 1/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.49 |
| ▸ | MELK | Q14680 | 1/20 | 0.49 |
| ▸ | MYLK3 | Q32MK0 | 1/20 | 0.49 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.49 |
| ▸ | TP53RK | Q96S44 | 1/20 | 0.49 |
| ▸ | RPTOR | Q8N122 | 2/20 | 0.44 |
| ▸ | MLST8 | Q9BVC4 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL927752 | 1.00 | ATM (0.52) | ATMATRKCNH2MTORPIK3CA | |
| SCHEMBL995881 | 0.90 | MTOR (0.62) | ATMATRKCNH2MTORPIK3CA | |
| SCHEMBL995880 | 0.90 | MTOR (0.62) | ATMATRKCNH2MTORPIK3CA | |
| SCHEMBL928344 | 0.88 | MTOR (0.61) | ATMATRKCNH2MTORPIK3CA | |
| SCHEMBL927267 | 0.88 | MTOR (0.54) | ATMATRKCNH2MTORPIK3CA | |
| SCHEMBL927764 | 0.88 | MTOR (0.58) | ATMATRMTORPIK3CAPIK3CD | |
| SCHEMBL927762 | 0.88 | MTOR (0.58) | ATMATRMTORPIK3CAPIK3CD | |
| SCHEMBL929486 | 0.87 | MTOR (0.55) | ATMATRKCNH2MTORPIK3CA | |
| SCHEMBL929485 | 0.87 | MTOR (0.55) | ATMATRKCNH2MTORPIK3CA | |
| SCHEMBL928839 | 0.87 | MTOR (0.66) | ATMATRKCNH2MTORPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2270008-B1 | 8-heteroaryl-3-alkyl-1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as PI-3 kinases inhibitors | NOVARTIS AG (CH) | 2012-10-03 | — | — | EP | claimed |
| US-7994170-B2 | 1,3-dihydro-imidazo[4,5-C]quinolin-2-ones as lipid kinase inhibitors | NOVARTIS AG (CH) | 2011-08-09 | — | — | US | claimed |
| EP-2292617-A1 | 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase and/or pi3 kinase inhibitors | Novartis AG (CH) | 2011-03-09 | — | — | EP | claimed |
| EP-2270008-A1 | 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase and/or pi3 kinases inhibitors | Novartis AG (CH) | 2011-01-05 | — | — | EP | claimed |
| US-20100056558-A1 | 1,3-DIHYDRO-IMIDAZO[4,5-C]QUINOLIN-2-ONES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-03-04 | — | — | US | claimed |
| US-20080194579-A1 | 1,3-Dihydro-Imidazo [4,5-C] Quinolin-2-Ones as Lipid Kinase Inhibitors | NOVARTIS AG (CH) | 2008-08-14 | — | — | US | claimed |
| US-9370508-B2 | Imidazoquinolines as dual lipid kinase and mTOR inhibitors | NOVARTIS AG (CH) | 2016-06-21 | — | — | US | disclosed |
| US-20130178479-A1 | PHARMACEUTICAL COMBINATIONS | NOVARTIS AG (CH) | 2013-07-11 | — | — | US | disclosed |
| US-8431592-B2 | 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase inhibitors | NOVARTIS AG (CH) | 2013-04-30 | — | — | US | disclosed |
| US-20120282252-A1 | 5Imidazoquinolines and Pyrimidine Derivatives as Potent Modulators of VEGF-Driven Angiogenic Processes | NOVARTIS AG (CH) | 2012-11-08 | — | — | US | disclosed |
| EP-2270008-B1 | 8-heteroaryl-3-alkyl-1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as PI-3 kinases inhibitors | NOVARTIS AG (CH) | 2012-10-03 | — | — | EP | disclosed |
| US-20120207751-A1 | Imidazoquinolines as lipid kinase inhibitors | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| EP-2292617-B1 | 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase and/or pi3 kinase inhibitors | NOVARTIS AG (CH) | 2012-07-11 | — | — | EP | disclosed |
| EP-2292617-A1 | 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase and/or pi3 kinase inhibitors | Novartis AG (CH) | 2011-03-09 | — | — | EP | disclosed |
| US-20110020338-A1 | 5Imidazoquinolines and Pyrimidine Derivatives as Potent Modulators of VEGF-Driven Angiogenic Processes | NOVARTIS AG (CH) | 2011-01-27 | — | — | US | disclosed |
| EP-2270008-A1 | 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase and/or pi3 kinases inhibitors | Novartis AG (CH) | 2011-01-05 | — | — | EP | disclosed |
| US-20100105696-A1 | IMIDAZOQUINOLINES AS DUAL LIPID KINASE AND mTOR INHIBITORS | NOVARTIS AG (CH) | 2010-04-29 | — | — | US | disclosed |
| US-20100056558-A1 | 1,3-DIHYDRO-IMIDAZO[4,5-C]QUINOLIN-2-ONES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-03-04 | — | — | US | disclosed |
| US-7667039-B2 | 1,3-dihydro-imidazo [4,5-C] quinolin-2-ones as lipid kinase inhibitors | NOVARTIS AG (CH) | 2010-02-23 | — | — | US | disclosed |
| US-20080194579-A1 | 1,3-Dihydro-Imidazo [4,5-C] Quinolin-2-Ones as Lipid Kinase Inhibitors | NOVARTIS AG (CH) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105696-A1 | IMIDAZOQUINOLINES AS DUAL LIPID KINASE AND mTOR INHIBITORS | MTOR, ULK1, RICTOR | ATM 1235/4885ATR 3067/4885KCNH2 2011/4885 |
| US-20100056558-A1 | 1,3-DIHYDRO-IMIDAZO[4,5-C]QUINOLIN-2-ONES AS LIPID KINASE INHIBITORS | PDPK1, PI4KA, PIP4K2A | ATM 1665/4885ATR 3330/4885KCNH2 1871/4885 |
| US-20120207751-A1 | Imidazoquinolines as lipid kinase inhibitors | PI4KA, PDPK1, PI4KB | ATM 197/4885ATR 328/4885KCNH2 1835/4885 |
| US-20130178479-A1 | PHARMACEUTICAL COMBINATIONS | MTOR, RICTOR, PIK3CA | ATM 545/4885ATR 725/4885KCNH2 4207/4885 |
| US-20120282252-A1 | 5Imidazoquinolines and Pyrimidine Derivatives as Potent Modulators of VEGF-Driven Angiogenic Processes | KDR, FLT4, TEK | ATM 3879/4885ATR 3288/4885KCNH2 3766/4885 |
| US-20080194579-A1 | 1,3-Dihydro-Imidazo [4,5-C] Quinolin-2-Ones as Lipid Kinase Inhibitors | PDPK1, PI4KA, PIP4K2A | ATM 1665/4885ATR 3330/4885KCNH2 1871/4885 |
| US-20110020338-A1 | 5Imidazoquinolines and Pyrimidine Derivatives as Potent Modulators of VEGF-Driven Angiogenic Processes | KDR, FLT4, TEK | ATM 3879/4885ATR 3288/4885KCNH2 3766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.